MDA News and Updates

[title]
MTM: Genetic Testing Study Open
April 18, 2013
Cure CMD, in collaboration with the Congenital Muscle Disease International Registry (CMDIR), Valerion Therapeutics (formerly 4s3 Bioscience), the University of Chicago, University of Michigan and Boston Children's Hospital, is sponsoring
[title]
MDA Scientific Conference To Emphasize Therapy Development
April 18, 2013
The Muscular Dystrophy Association’s annual conference being held in Washington, D.C., on April 21-24, 2013, is centered on the theme Therapy Development for Neuromuscular Diseases: Translating Hope into Promise.
[title]
MDA and ALS TDI: Partnership Extended Through 2013
April 17, 2013
MDA and the nonprofit biotech ALS Therapy Development Institute (ALS TDI) have extended their strategic research partnership through 2013.
[title]
FDA Approves ALS Stem Cell Trial
April 17, 2013
Maryland biotherapeutics company Neuralstem today announced that it has received approval from the U.S.
[title]
DMD/BMD: MDA Funds Development of Drug to Fix Calcium Leaks
April 16, 2013
MDA has awarded $1 million to biopharmaceutical company ARMGO Pharma for development of a new strategy for treating Duchenne muscular dystrophy (DMD) or
[title]
DMD: FDA Asks Sarepta for More Data on Eteplirsen
April 15, 2013
The U.S.
[title]
Joan Jett And The Blackhearts To Headline MDA Ride For Life XXVI
April 15, 2013
[title]
SMA Research Briefs: Testing Drugs from Other Diseases
April 15, 2013
In the search for therapies for spinal muscular atrophy (SMA), researchers are testing two drugs with connections to other neuromuscular disorders: riluzole, which is approved for use in
[title]
Study Finds that Cognitive Status Predicts Functional Decline in ALS
April 11, 2013
The presence of cognitive impairment within the first year after a diagnosis of amyotrophic lateral sclerosis (ALS) may be associated with more rapid decline in muscle function, a team of researchers in Ireland has reported.
[title]
DMD: Drisapersen Outperforms Placebo in Walking Test
April 11, 2013
The exon-skipping drug drisapersen has shown encouraging results in an international phase 2b trial in boys with Duchenne muscular dystr
[title]
Free Eye Exams for Service Animals: Now Scheduling May Appointments
April 09, 2013
Registration is now open for the 6th Annual ACVO/Merial Service Dog Eye Exam Event, which offers free eye exams for service animals during the month of May.
[title]
DMD: Eteplirsen Shows Continued Benefit at 74 Weeks; Data To Be Announced at MDA Conference
April 05, 2013
Eteplirsen, an experimental exon-skipping therapy designed to treat Duchenne muscular dystrophy (DMD) caused by specific m
[title]
Newly Developed FSHD Mice Likely To Aid Research
April 04, 2013
A newly developed research mouse that has the same combination of genetic alterations that causes human facioscapulohumeral muscular dystrophy (FSHD) is expected to change the way research in this disease is conducted, possibly speeding the development of therapies.
[title]
Survey Open for People with ALS
April 02, 2013
An online survey about ALS symptoms, now open to people with amyotrophic lateral sclerosis (ALS), is being conducted by the Neurological Clinical Research Institute at Massachusetts General Hospital (MGH) in Boston.
[title]
ALS Research Briefs: Role of Astrocytes in ALS
March 29, 2013
Scientists continue to work at uncovering the biological mechanisms underlying amyotrophic lateral sclerosis (ALS). One area of intense study involves the potential role of central nervous system support cells called astrocytes. 
[title]
Research Briefs: DMD, Leigh Syndrome, MG, Periodic Paralysis, Pompe Disease
March 26, 2013
Drug development and identifying new leads for possible drug development are in the news for five neuromuscular diseases in MDA’s program.
[title]
MDA and ALSA Urge FDA to Take Action on Groundbreaking ALS Hearing
March 25, 2013
The Muscular Dystrophy Association and The ALS Association (ALSA) submitted a joint comment to the U.S. Food and Drug Administration (FDA) today, commending and thanking the agency for convening its first-ever ALS public hearing on Feb.
[title]
Government Funding for NMD Research Largely Spared in Continuing Resolution
March 25, 2013
The news is generally favorable for many important government-funded neuromuscular disease research projects, in the wake of Congress’ recent passage of a continuing resolution funding the government through the end of September. 
[title]
ALS Research Briefs: Rasagiline and NurOwn
March 22, 2013
The latest advances in brain and central nervous system research were discussed at the 65th annual meeting of the American Academy of Neurology, held in San Diego, March 16-23, 2013.
[title]
SMA Antisense Drug Shows Safety, Tolerability in Phase 1 Trial
March 21, 2013
An experimental drug designed to treat the underlying molecular defect in spinal muscular atrophy (SMA) has shown encouraging results in a phase 1 trial.
MDA in Your Community


Stay informed. Stay involved.
Sign up for MDA News